PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway

CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.PMID:38306024 | DOI:10.3233/CBM-230090

Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Sixu Zhou Baogui Wang Yingying Wei Peiru Dai Yan Chen Yingyi Xiao Hongmei Xia Chunlin Chen Weihua Yin Source Type: research